RaltegravirIn Treatment-Naive Patients with HIV-1 Infection

被引：0
|
作者：
Jamie D. Croxtall
Lesley J. Scott
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2010年 / 70卷
关键词：
Tenofovir; Efavirenz; Virological Failure; Raltegravir; Integrase Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Raltegravir, a first-in-class, oral HIV type-1 (HIV-1) integrase inhibitor, blocks the covalent integration of HIV-1 complementary DNA into the host genome.
引用
收藏
页码：631 / 642
页数：11
相关论文
共 50 条
  • [41] HIV Increases Mean Platelet Volume During Asymptomatic HIV Infection in Treatment-Naive Patients
    Bello, Laura
    Serrano, Joaquin
    Balinas, Josefa
    Pedreira, Jose D.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (05) : E112 - E113
  • [42] Association of High Ratio of CSF/Plasma HIV-1 RNA with Central Nervous System Co-Infection in HIV-1-Positive Treatment-Naive Patients
    Liu, Qian
    Tao, Wendan
    Yang, Honghong
    Wu, Yushan
    Yu, Qing
    Liu, Min
    BRAIN SCIENCES, 2022, 12 (06)
  • [43] Determinants of HIV-1 drug resistance in treatment-naive patients and its clinical implications in an antiretroviral treatment program in Cameroon
    Zoufaly, Alexander
    Jochum, Johannes
    Hammerl, Raffaela
    Nassimi, Nilofar
    Raymond, Yurika
    Burchard, Gerd-Dieter
    Schmiedel, Stefan
    Drexler, Jan-Felix
    Kay, Campbell Naomi
    Taka, Nchang
    Awasom, Charles
    Metzner, Karin
    Jan, van Lunzen
    Feldt, Torsten
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 83 - 84
  • [44] Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients
    Kozal, MJ
    Hullsiek, KH
    Leduc, R
    Novak, RM
    MacArthur, RD
    Lawrence, J
    Baxter, JD
    ANTIVIRAL THERAPY, 2006, 11 (04) : 457 - 463
  • [45] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [46] HIV-1 genotypic resistance in treatment-naive subjects enrolled in an observational trial (GAIN)
    Becker, MI
    Haubrich, R
    Wesselman, CW
    Garrett, L
    Lee, SY
    Millard, D
    Baxter, JD
    ANTIVIRAL THERAPY, 2002, 7 : S175 - S175
  • [47] COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN SPAIN
    Davis, A. E.
    Brogan, A. J.
    Goodwin, B. B.
    Nocea, G.
    Lozano, V
    VALUE IN HEALTH, 2016, 19 (07) : A410 - A410
  • [48] Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection
    Landovitz, Raphael J.
    Angel, Jonathan B.
    Hoffmann, Christian
    Horst, Heinz
    Opravil, Milos
    Long, Jianmin
    Greaves, Wayne
    Faetkenheuer, Gerd
    JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (08): : 1113 - 1122
  • [49] Characteristics of antiretroviral treatment-naive patients with HIV-1 B and non-B subtypes in western Sydney
    Varma, R.
    Sawleshwarkar, S.
    Herring, B.
    Wong, A.
    Thappa, K.
    Couldwell, D.
    Dominic, D.
    HIV MEDICINE, 2014, 15 : 87 - 88
  • [50] Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients
    Stephan, Christoph
    Baldauf, Hanna-Mari
    Barry, Joanne
    Giordano, Frank A.
    Bartholomae, Cynthia C.
    Haberl, Annette
    Bickel, Markus
    Schmidt, Manfred
    Laufs, Stephanie
    Kaderali, Lars
    Keppler, Oliver T.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2809 - 2818
12345